Description
Inclusion Criteria:
- * Ability to understand and willingness to sign a written informed consent document.
- * Age β₯18 years.
- * Newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas.
- * Tumor must be resectable.
- * Patient's acceptance to have a tumor biopsy.
- * ECOG performance status 0 or 1
- * Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
- * For both Women and Men, must use acceptable form of birth control while on study.
Exclusion Criteria:
- * Have received any anti-pancreatic cancer therapy.
- * Have been diagnosed with another malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study.
- * Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures
- * Subjects with active, known or suspected autoimmune disease that may relapse.
- * Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.
- * Active infection requiring systemic therapy.
- * Infection with HIV or hepatitis B or C at screeningβ’
- * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.
- * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
- * Prior allogeneic stem cell transplantation or organ transplantation
- * Any major surgical procedure requiring general anesthesia β€ 28 days before first dose of study drug.
- * Have received a live vaccine β€ 28 days before first dose of study drug.
- * Use of QT prolonging drugs within 2 weeks before the start of SX-682 dosing and for the length of the study.
- * ECG demonstrating a QTc interval β₯ 470 msec or patients with congenital long QT syndrome.
- * Severe hypersensitivity reaction to any monoclonal antibody.
- * Concurrent participation in another therapeutic clinical study
- * Pregnant or breastfeeding
Ages Eligible for Study:
18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
No